COVID-19 Vaccine: US Drugmaker Pfizer Now Expects US$33.5 Billion Revenue
Pfizer, a US drugmaker Wednesday sharply increased its 2021 projection for revenues tied to its COVID-19 vaccine forecasting generating US$33.5-billion in sales instead of US$26-billion predicted in May.
The company which has partnered with Germany’s BioNTech on the vaccine is estimating to deliver 2.1 billion doses.
Pfizer Chief Executive Albert Bourla said more than a billion doses of the vaccine have been delivered, saying “the speed and efficiency of our efforts with BioNTech to help vaccinate the world against COVID-19 have been unprecedented.”
Pfizer said the pre-tax profit margin on the COVID-19 vaccine sales was in the “high-20s” in terms of per cent, the same as the earlier forecast.
The drugmaker reported second-quarter profits of $5.6-billion, up 59 per cent from the year-ago period on a 92 per cent increase in revenues to $19 billion.
HOT DEALS:
itel A70 - (128GB, 3GB RAM) $89,
itel A70 - (256GB, 4GB RAM) $99
itel P40 (128GB, 4GB), (6000mAh) $99
itel P40 (64GB, 4G), (6000mAh) $93
Cash on Delivery in Harare & Bulawayo. Tinotumira kwamuri inosvika.
WhatsApp: 0783 450 793
- Pfizer pushes for a third shot as Delta drives global outbreaks
- Pfizer/BioNTech To Produce COVID-19 Vaccine In South Africa
- COVID-19 Vaccine: 23 Die Within Days Of Receiving Pfizer
- COVID-19 Vaccines Do Not Harm Sperm Count – Study
- Local Health Expert Explains Norwegian COVID-19 Vaccine Deaths
Pfizer has launched clinical studies on a possible third dose of the COVID-19 vaccine as a booster shot. Bourla has said such boosters could amount to a “durable” revenue stream for the company.
US health officials have thus far not far backed a third shot for the broad population, but officials are studying the need for a third shot in immunocompromised people.
More: AFP
